First-Of-Its-Kind Test Identifies Autism Risk at Birth
Posted on 03 Feb 2026
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age of diagnosis remains around five years, well after critical periods of brain development. Diagnosis is still largely based on behavioral observation, which delays intervention and limits long-term potential. A newly launched clinical test now offers a way to identify autism risk at the cellular level, potentially as early as birth.
The test, called ASD Insight, has been developed by NeuroQure (Irvine, CA, USA) and builds on decades of research linking autism to dysregulated calcium signaling and mitochondrial dysfunction. Using an advanced optical patch clamp technique, the test detects abnormalities in cellular signaling pathways associated with autism risk.
ASD Insight analyzes living cells obtained from a small skin biopsy, enabling direct measurement of mitochondrial and neurotransmitter function rather than relying solely on genetic screening. Samples are processed in NeuroQure’s CLIA-certified laboratory, and clinicians receive individualized risk assessments within weeks. This method enables detection of biophysical and metabolic dysfunctions before behavioral symptoms appear.
Multiple studies have shown that children who begin autism treatment by age two experience meaningful gains in language, cognition, and social functioning, with many achieving independent living and workforce participation. Emerging evidence suggests that effective interventions can begin as early as six months of age. In contrast, delayed diagnosis is associated with greater long-term dependency and substantially higher lifetime medical costs.
By enabling autism risk assessment at or near birth, ASD Insight could shift clinical practice toward proactive, biology-driven care. Earlier identification allows families and clinicians to initiate targeted therapies during the most sensitive stages of neurodevelopment. The company aims to support broader adoption of early screening so that intervention decisions can be made months or years earlier than is currently possible.
“Simply put, early diagnosis means early treatment, and early treatment leads to brighter futures,” said David Justus, Founder & CEO of NeuroQure. “With this test, we can provide families with the knowledge they and their physicians need to make informed decisions about their child’s development from the very start, significantly impacting the trajectory of their lives.”
Related Links:
NeuroQure
